Melatonin in osteosarcoma: An effective drug?

Medical Hypotheses

Volumn 48, Issue 6, 1997, Pages 523-525

  Panzer, A ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN;

BONE GROWTH; CANCER HORMONE THERAPY; DRUG EFFICACY; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0030762496     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90123-7     Document Type: Article

References (36)

1. Mertens W C, Bramwell V. Osteosarcoma and other tumours of bone. Current Opinion in Oncology 1994; 6: 384-390.
2. Meyers P A, Heller G, Healey J H et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11(3): 449-453.
3. Bartsch H, Bartsch C, Flehmig B. Differential effect of melatonin on slow and fast growing passages of a human melanoma cell line. Neuroendocrinol Lett 1986; 8: 289.
4. Karasek M, Kunert-Radek J, Stepien H, Pawlikowski M. Melatonin inhibits the proliferation of estrogen-induced rat pituitary cells in vitro. Neuroendocrinol Lett 1986; 10: 135.
5. Leone A M, Silman R E, Hill B T, Whelan R D H, Shellard S A. Growth inhibitory effects of melatonin and its metabolites against ovarian tumour cell lines in vitro. In: Gupta D, Attanasio A, Reiter R J, eds. The Pineal Gland and Cancer. Tubingen: Brain Research Promotion, 1988: 273-281.
6. Barni S, Lissoni P, Cazzaniga M et al. A randomized study of low-dose subcutaneous Interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-Fluorouracil and Folates. Oncology 1995; 52: 243-245.
7. Lissoni P, Barni S, Meregalli S et al. Modulation of cancer endocrine therapy by melatonin: a Phase 2 study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995; 71: 854-856.
8. Lissoni P, Barni S, Ardizzoia A et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994; 73: 699-701.
9. Aldeghi R, Lissoni P, Barni S, Ardizzoia A et al. Low-dose Interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metaststic hepatocellular carcinoma. Eur J Cancer 1994; 30A(2): 167-170.
10. Lissoni P, Tisi E, Barni S, Ardizzoia A et al. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer 1992; 66: 155-158.
11. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S. Subcutaneous therapy with low-dose Interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993; 79: 401.
12. Attanasio A, Borelli P, Gupta D. Circadian rhythms in serum melatonin from infancy to adolescence. J Clin Endocrinol Metab 1985; 61: 388-390.
13. Waldhauser F, Weiszenbacher G, Frisch H, Zeitlhuber U. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1984: 362-364.
14. Rager K, Kozak I, Gupta D, Attanasio A. 6-hydroxymelatonin sulfate excretion in children from newborn age to adulthood. In: Reiter R J, Pang S F, eds. Advances in Pineal Research. London: John Libbey, 1989: 299-304.
15. Gupta D. How important is the pineal gland in children? In: Reiter R J, Pang S F, eds. Advances in Pineal Research. London: John Libbey, 1989: 291-297.
16. Starr K W. Hormonal imbalance and the sarcomata. Aust NZ J Surg 1969; 39(2): 142-150.
17. Lissoni P, Barni S, Brivio F et al. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer 1995; 3(3): 194-197.
18. Lissom P, Barni S, Cazzaniga M et al. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose 11-2 in patients with advanced solid tumors who had progressed on 11-2 alone. Oncology 1994; 51(4): 344-347.
19. Lissoni P, Meregalli S, Fossati V et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994; 80(6): 464-467.
20. Lissoni P, Barni S, Addizzoia A et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced non-small cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992; 49(5): 336-339.
21. Lissoni P, Meregalli S, Nosetto L et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996; 53(1): 43-46.
22. Lissoni P, Ardizzoia A, Barni S et al. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast cancer patients. Oncology Reports 1995; 2: 871-873.
23. Lissoni P, Ardizzoia A, Meregalli S et al. A clinical study of immunotherapy versus endocrine therapy versus chemotherapy in the treatment of advanced pancreatic adenocarcinoma. Oncology Reports 1994; 1: 1277-1280.
24. Das U N. Melatonin in the pathobiology and treatment of cancer. Cancer J 1995; 8(3): 103-108.
25. Lissoni P, Brivio F, Barni S et al. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension. Anticancer Res 1990; 10(6): 1759-1761.
26. Lissoni P. Barni S, Brivio F et al. A biological study on the efficacy of low-dose, subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology 1995; 52(5): 360-362.
27. Lissoni P, Barni S, Tancini G et al. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology 1993; 50: 399-402.
28. Viviani S, Negretti E, Orazi A et al. Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res 1990; 8(4): 347-354.
29. Lissoni P, Brivio F, Brivio O et al. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Homeost Agents 1995; 9(1): 31-33.
30. Lissoni P, Barni S, Cattaneo G et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology 1991; 48(6): 448-450.
31. Bartsch C, Bartsch H, Lippert T H. Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug. In Vivo 1995; 9: 305-310.
32. Reiter R J. The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Neurochem Int 1995; 27(6): 453-460.
33. Cos S, Blask D E, Lemus-Wilson A, Hill A B. Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res 1991; 10: 36-42.
34. Conti A, Maestroni G J M. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 1995; 19: 103-110.
35. Neri B, Brocchi A, Carossino A M et al. Effects of melatonin administration on cytokine production in patients with advanced solid tumors. Oncology Reports 1995; 2: 45-47.
36. Giordano M, Palermo M S. Melatonin-induced enhancement of antibody-dependent cellular cytotoxicity. J Pineal Res 1991; 10: 117-121.